Active Share (vs S&P 500): 100.0%
· vs QQQ: 100.0%
— share of the book that differs from index weights (higher = more active)
· ranking
Est. Qtr Return (Q2 2026 → Q3 2026):
-2.5%
· vs SPY
-4.6%
· Prev Value $1.33B
— last quarter positions weighted by this quarter price moves
· ranking
Est. QTD Return (Q3 2026 → newest close):
-4.0%
· vs SPY
-6.2%
· Latest Value $1.15B
— latest reported positions valued at quarter-to-date price moves (still in progress)
· ranking
In its Q3 2026 13F filing, Boxer Capital Management, LLC disclosed 47 equity positions with a combined reported value of $1.15B. The filing implies a focused portfolio: its ten largest positions account for 71.4% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q3 2026 were TNGX ($262.63M), KOD ($140.08M), RVMD ($102.63M). By sector, the heaviest allocations are Health Care 99.6%, Other 0.4%. Versus the prior quarter, allocation shifted toward Health Care (+1.0pp) and away from Other (-1.0pp).
Versus the prior quarter, Boxer Capital Management, LLC opened 12 new positions, trimmed 13 and fully exited 28, a turnover rate of 70.7% of positions. The portfolio's overlap with the prior quarter was 47% of names.
The largest new positions opened in Q3 2026 were ACHV ($17.39M), CCCC ($13.82M), TRAX ($8.51M).
Of the 28 positions fully exited versus the prior quarter, the largest were VIR ($19.01M), PCVX ($18.89M), CRVS ($16.43M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
Latest Boxer Capital Management, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Boxer Capital Management, LLC is an SEC-registered 13F filer based in San Diego, CA, United States. As of Q3 2026 it reported 47 US equity positions with a combined value of $1.15B. HoldingsHub carries 8 quarters of its filings (Q4 2024–Q3 2026).
Regulatory AUM (Form ADV): $578.22M as of 2026-05-11
Client mix (by RAUM): pension and profit-sharing plans 100%
Manages 2 private funds, of which 2 hedge funds
Website: boxercap.com
Portfolio Structure
47 positions · $1.15B reported value (Q3 2026)
Top 10 holdings = 71.4% of reported value
Largest position: TNGX (TANGO THERAPEUTICS INC) at 22.8%
Average position size: $24.48M
Sector Tilt
Health Care 99.6%
(classified holdings cover 100% of value)
Quarterly Activity
Q3 2026: 12 new, 9 added, 13 reduced, 28 exited
13 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
AI Rebalance Analysis
1. Overall direction and market view: The fund is actively reducing exposure to high-weight positions (e.g., TNGX, QURE) while selectively adding to smaller biotech names, suggesting a cautious stance on large holdings but optimism in niche biotech/therapeutic plays. Heavy sector concentration in Health Care indicates a specialized, high-risk/high-reward view.
2. Key moves:
- Reduced: TNGX (shares -3.2%), ABVX (-21.5%), PGEN (-16.1%), QURE (-5.3%).
- Added: KYMR (+22.2% shares), REPL (+7.4%), SRZN (+23.1%).
- Held: KOD, RVMD, CORT (no share changes).
3. Portfolio structure: Highly active, concentrated in Health Care (biotech/therapeutics), with appetite for speculative, high-growth names (e.g., REPL, SRZN). Passive elements are minimal.
4. Per-holding one-liner:
- TNGX: Biotech (TANGO THERAPEUTICS) – cancer therapeutics.
- KOD: Biotech (KODIAK SCIENCES) – ophthalmology drugs.
- RVMD: Biotech (REVOLUTION MEDICINES) – RAS pathway inhibitors.
- KYMR: Biotech (KYMERA THERAPEUTICS) – dermatology/anti-inflammatories.
- REPL: Biotech (REPLIMUNE GROUP) – oncolytic virus immunotherapy.
- ABVX: Biotech (ABIVAX SA) – hepatitis/HIV treatments.
- SRZN: Biotech (SURROZEN INC) – reproductive health (unverified).
- CORT: Biotech (CORCEPT THERAPEUTICS) – Cushing’s syndrome drugs.
- PGEN: Biotech (PRECIGEN INC) – gene therapy (unverified).
- QURE: Biotech (UNIQURE NV) – genetic disorder treatments.
5. Style summary: Concentrated biotech fund tactically trimming large caps to double down on high-growth, speculative therapeutic plays.
Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 10:50
Every 13F share count is marked to the quarter-end close, rebuilding the NAV this
portfolio would have earned had it done nothing all quarter. This is a historical
reconstruction from already-public filings and prices — not a model forecast, so
precision/recall do not apply.
2025-Q3 = 100. Solid = reconstructed NAV, dashed = SPY benchmark.
Prices are split-adjusted closes and exclude dividends, so dividend-heavy
portfolios would in reality sit slightly above this line.
This portfolio is broadly diversified (Top-10 = 70.0% of reported value), so a
Top-10 proxy cannot represent the whole fund — only the full-holdings reconstruction is shown.
Why there is no forecast NAV
Not published because:
Top-10 covers < 85% of reported value · Holdings-forecast backtest F1 < 0.80 · Top-10 quarterly turnover > 20%
Source: full 13F positions marked to quarter-end closes (computed 2026-11-02 01:13:11).
Share counts and prices are used as a ratio, so splits cancel out.
Holdings Prediction Model
Predicts next-quarter Top-10 holdings and weights from the fund's own historical
trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative
volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through
quarter T. Weights are shares of the modelled portfolio.
The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.
Latest-Quarter Accuracy (2026-Q3)
P 70%R 70%F1 70%(modelled on 2026-Q2; 7/10 hit)
Low-confidence forecast
This fund replaces about 40% of its Top-10 each quarter and
backtests at F1 62% (threshold 80%).
Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.
★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.
Barra Factor Attribution
The disclosed long US equity book from the 2026-Q3 13F is held at its
report-date weights and decomposed over 2026-09-30 ~ 2026-11-16.
The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional
factor returns and an EWMA factor covariance for risk. The “portfolio” is the
visible 13F book, not the fund's true NAV.
The quarter is not complete yet; the window ends at the latest available price date, 2026-11-16, and will update as prices arrive.
Portfolio return-10.15%Buy & hold
QQQ synthetic benchmark-17.01%Liquidity weighted
Excess return+6.86%vs benchmark
Barra annualised vol73.4%Model estimate
Realised vol66.7%Annualised in window
Weighted beta1.32Raw exposure
Factor / specific risk28% / 72%Share of variance
Top-10 concentration100.0%Of reported value
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.
1. Performance
Metric
Value
Note
Portfolio return (buy & hold)
-10.15%
Disclosed long book
QQQ synthetic benchmark
-17.01%
Liquidity-weighted constituents
Model universe, equal weight
-1.70%
Opportunity-cost reference
Excess return
+6.86%
Portfolio − benchmark
Arithmetic return sum
-7.78%
Difference vs compounded is the cross term
Weighted raw beta
1.32
Weighted holding betas
Realised volatility (annualised)
66.75%
Daily returns in window
Barra model volatility (annualised)
73.39%
Factor + specific
Factor share of variance
27.8%
Barra factors
Specific share of variance
72.2%
Stock residuals
Reported value
$442.9M
13F long US equity
2. Return attribution
The -7.78% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.
Factor group
Factors
Contribution
Share of |return|
Size & Liquidity
6
+0.20%
2.6%
Momentum & Growth
3
-12.51%
-160.8%
Volatility & Tail Risk
7
-3.46%
-44.5%
Industry
12
+6.98%
89.8%
Specific
1
+1.00%
12.8%
Factor
Type
Exposure
Factor return
Contribution
Share of |return|
Residual Volatility
Style
+2.71
+3.29%
+8.91%
114.6%
Health Care
Industry
+1.00
+6.98%
+6.98%
89.8%
Size
Style
-1.42
-1.95%
+2.77%
35.6%
Non-linear Size
Style
+2.37
+1.01%
+2.39%
30.8%
Beta
Style
+0.47
+4.44%
+2.07%
26.7%
Specific
Specific
—
—
+1.00%
12.8%
Kurtosis
Style
+0.09
+7.51%
+0.68%
8.7%
Liquidity
Style
+0.36
+0.36%
+0.13%
1.7%
Short-term Reversal
Style
-0.21
+0.87%
-0.18%
-2.3%
Max Drawdown
Style
+0.13
-1.76%
-0.23%
-2.9%
Leverage (Downside Vol)
Style
+0.22
-1.71%
-0.38%
-4.9%
Turnover
Style
+0.11
-4.80%
-0.55%
-7.1%
Growth
Style
-0.49
+1.75%
-0.86%
-11.1%
Amihud Illiquidity
Style
+2.13
-0.45%
-0.95%
-12.2%
Skewness
Style
+0.49
-4.39%
-2.14%
-27.5%
Mid Cap
Style
+1.85
-1.94%
-3.59%
-46.1%
Momentum
Style
+2.87
-4.00%
-11.47%
-147.4%
Historical Volatility
Style
+0.88
-14.00%
-12.37%
-159.1%
3. Risk attribution
Annualised volatility is 73.39%; factor risk explains 27.8% of variance and specific risk 72.2%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.
Factor
Type
Exposure
Share of variance
Vol contribution
Share of vol
Specific
Specific
—
72.2%
+53.01%
53.0%
Momentum
Style
+2.87
8.8%
+6.47%
6.5%
Health Care
Industry
+1.00
4.9%
+3.60%
3.6%
Residual Volatility
Style
+2.71
4.5%
+3.26%
3.3%
Mid Cap
Style
+1.85
2.5%
+1.87%
1.9%
Size
Style
-1.42
1.9%
+1.40%
1.4%
Historical Volatility
Style
+0.88
1.7%
+1.23%
1.2%
Beta
Style
+0.47
1.6%
+1.16%
1.2%
Amihud Illiquidity
Style
+2.13
0.9%
+0.69%
0.7%
Non-linear Size
Style
+2.37
0.6%
+0.42%
0.4%
Growth
Style
-0.49
-0.3%
-0.21%
-0.2%
4. Style exposures
Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.
Style factor
Portfolio
QQQ benchmark
Difference
Size
-1.42
+2.10
-3.52
Non-linear Size
+2.37
+1.68
+0.69
Mid Cap
+1.85
+0.13
+1.73
Beta
+0.47
+1.29
-0.83
Momentum
+2.87
+0.72
+2.15
Short-term Reversal
-0.21
-0.64
+0.44
Residual Volatility
+2.71
-0.40
+3.11
Historical Volatility
+0.88
+0.86
+0.02
Liquidity
+0.36
+0.11
+0.25
Amihud Illiquidity
+2.13
+1.16
+0.97
Turnover
+0.12
+0.21
-0.09
Growth
-0.49
+0.58
-1.08
Leverage (Downside Vol)
+0.22
+0.14
+0.08
Skewness
+0.49
+0.24
+0.25
Kurtosis
+0.09
+0.21
-0.12
Max Drawdown
+0.13
-0.08
+0.21
5. Industry allocation & Brinson
Sector
Portfolio
Benchmark
Portfolio ret
Benchmark ret
Allocation
Selection
Interaction
Total
Information Technology
0.0%
73.6%
+0.00%
-22.33%
+3.83%
+16.44%
-16.44%
+16.44%
Communication Services
0.0%
2.6%
+0.00%
-17.64%
+0.01%
+0.46%
-0.46%
+0.46%
Utilities
0.0%
0.8%
+0.00%
+11.13%
-0.22%
-0.09%
+0.09%
-0.09%
Consumer Staples
0.0%
0.8%
+0.00%
+15.26%
-0.27%
-0.13%
+0.13%
-0.13%
Consumer Discretionary
0.0%
8.8%
+0.00%
+3.76%
-1.84%
-0.33%
+0.33%
-0.33%
Industrials
0.0%
11.1%
+0.00%
+4.36%
-2.39%
-0.48%
+0.48%
-0.48%
Health Care
100.0%
1.7%
-10.48%
+8.29%
+24.98%
-0.32%
-18.44%
-10.62%
Total
+23.98%
+15.52%
-34.28%
+5.22%
6. Holdings & contribution
Symbol
Name
Sector
Weight
Return
Contribution
QoQ
TNGX
TANGO THERAPEUTICS INC
Health Care
59.30%
-3.13%
-1.85%
Reduce
RVMD
REVOLUTION MEDICINES INC
Health Care
23.17%
-18.70%
-4.33%
Hold
CORT
CORCEPT THERAPEUTICS INC
Health Care
8.73%
-39.93%
-3.48%
Hold
PTGX
PROTAGONIST THERAPEUTICS INC
Health Care
5.41%
-11.40%
-0.62%
Hold
CTNM
CONTINEUM THERAPEUTICS INC
Health Care
1.50%
-27.94%
-0.42%
Hold
MAZE
MAZE THERAPEUTICS INC
Health Care
1.08%
+24.72%
+0.27%
New
RLAY
RELAY THERAPEUTICS INC
Health Care
0.81%
-4.32%
-0.03%
Reduce
Contribution rank
Symbol
Sector
Weight
Return
Contribution
1
MAZE
Health Care
1.08%
+24.72%
+0.27%
2
RLAY
Health Care
0.81%
-4.32%
-0.03%
3
CTNM
Health Care
1.50%
-27.94%
-0.42%
4
PTGX
Health Care
5.41%
-11.40%
-0.62%
5
TNGX
Health Care
59.30%
-3.13%
-1.85%
6
CORT
Health Care
8.73%
-39.93%
-3.48%
7
RVMD
Health Care
23.17%
-18.70%
-4.33%
7. Conclusions
Over the attribution window 2026-09-30 → 2026-11-16 (33 trading days), the reported portfolio returned -10.15%, versus -17.01% for the QQQ synthetic benchmark — an excess of +6.86%.
Return attribution: the largest positive style/industry contributions came from Residual Volatility +8.91%, Health Care +6.98%, Size +2.77%; the largest drags came from Historical Volatility -12.37%, Momentum -11.47%, Mid Cap -3.59%. Specific (stock-level) return contributed +1.00%.
Risk attribution: Barra model volatility is 73.39% annualised; factor risk explains 28% of variance and specific risk 72%. The largest factor risk sources are Momentum 8.8%, Health Care 4.9%, Residual Volatility 4.5%.
Style tilt: size -1.42, momentum +2.87, volatility +0.88, liquidity +0.36; the weighted raw beta is 1.32. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
Industry: the largest overweight versus the benchmark is Health Care (+98.3 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +23.98%, selection +15.52% and interaction -34.28%.
Concentration: the top-10 positions are 100.0% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.
FAQ
What did Boxer Capital Management, LLC buy in 2026-Q3?
In its 2026-Q3 13F filing, Boxer Capital Management, LLC reported 47 equity positions worth $1.15B in aggregate; its largest disclosed positions were TNGX ($262.63M), KOD ($140.08M), RVMD ($102.63M).
How large is Boxer Capital Management, LLC's portfolio?
Boxer Capital Management, LLC reported $1.15B of long equity holdings across 47 positions as of 2026-Q3. Top-10 holdings account for 71.4% of reported value.
What is Boxer Capital Management, LLC's investment style?
HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.
Embed this fund on your site
Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.
<iframe src="https://holdingshub.top/funds/boxer-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>